Download presentation
Presentation is loading. Please wait.
Published byAllison Blankenship Modified over 9 years ago
1
DEVELOPMENT AND UTLILITY OF DIRECT ALCOHOL BIOMARKERS
UNITED STATES DRUG TESTING LABORATORIES, INC. DEVELOPMENT AND UTLILITY OF DIRECT ALCOHOL BIOMARKERS CHARLES A. PLATE, Ph.D. LABORATORY DIRECTOR Testing Innovation Research Development
2
PROPERTIES OF SELECTED INDIRECT ALCOHOL BIOMARKERS
Testing Innovation Research Development
3
PROPERTIES OF DIRECT ALCOHOL BIOMARKERS
Testing Innovation Research Development
4
STRUCTURE OF ETHYL GLUCURONIDE
Testing Innovation Research Development
5
STRUCTURE OF ETHYL SULFATE
Testing Innovation Research Development
6
SYNTHESIS OF ETHYL GLUCURONIDE AND ETHYL SULFATE
UDP-GLUCURONYL GLUCURONATE + EtOH ETHYL GLUCURONATE TRANSFERASE SULFOTRANSFERASE SULFATE + EtOH ETHYL SULFATE Testing Innovation Research Development
7
EtG / EtS IN URINE Confirms alcohol exposure for up to 5 days following consumption. -Glucuronidase from urinary tract infections destroys EtG but not EtS. Cut-offs are variable and can be set to meet client’s needs. Innocent-positives can be generated by alcohol-containing hand sanitizers and mouthwashes. Testing Innovation Research Development
8
EtG ANALYSIS EtG Cal 500 ng/ml Testing Innovation Research Development
9
EtS ANALYSIS EtS Cal 125 ng/ml 125.0/80.0
Testing Innovation Research Development
10
EtG / EtS IN URINE Positive EtG/EtS is NOT unequivocal evidence of beverage alcohol consumption. Positive EtG/EtS requires further examination, either clinically or by using a biomarker assay with a higher exposure threshold for positivity. Testing Innovation Research Development
11
USE OF EtG / EtS IN URINE Determination of alcohol ingestion
Window of measure = days Indicates that alcohol has been consumed Primarily used for monitoring in enforced abstinence programs (impaired professionals) Testing Innovation Research Development
12
STRUCTURE OF PHOSPHATIDYLETHANOL
Testing Innovation Research Development
13
SYNTHESIS OF PHOSPHATIDYLETHANOL
PHOSPHOLIPASE D PHOSPHATIDYLCHOLINE + EtOH PHOSPHATIDYLETHANOL Testing Innovation Research Development
14
PHOSPHATIDYLETHANOL IN BLOOD
A direct alcohol biomarker that incorporates into cell membranes Long half-life--not metabolized Remains in red cell membrane for the life of the blood cell or spontaneous hydrolysis - 3 weeks Can be detected following ingestion of 200 grams of ethanol over 1 week Window of detection 3 weeks or longer Testing Innovation Research Development
15
PHOSPHATIDYLETHANOL ANALYSIS
701.3/255.0 701.3/281.0 Testing Innovation Research Development
16
USE OF PHOSPHATIDYLETHANOL IN BLOOD
Determination of longer term alcohol abuse Window of measure up to 3 weeks Indicates heavy drinking over 3 week period Identifies potential problem drinkers Could be used to screen transplant recipients Testing Innovation Research Development
17
FATTY ACID ETHYL ESTER STRUCTURE OF ETHYL OLEATE
Testing Innovation Research Development
18
SYNTHESIS OF FATTY ACID ETHYL ESTERS (FAEE’s)
LONG CHAIN ACYL-CoA:ETHANOL FATTY ACIDS + EtOH FATTY ACID ETHYL ESTERS O-ACYLTRANSFERASE Testing Innovation Research Development
19
FAEE’s IN MECONIUM Meconium is earliest stool of newborn containing intestinal epithelial cells, mucus, lanugo, amniotic fluid, bile, and water; tar-like, sterile and odorless FAEE’s present in meconium of infants delivered from known alcoholics Detection of FAEE’s in meconium currently “gold standard” method of identifying infants exposed to alcohol in utero Testing Innovation Research Development
20
FAEE ANALYSIS FAEE’s are isolated from meconium using a solid-phase extraction technique FAEE’s are analyzed using positive ion (PCI) chemical ionization gas chromatography / mass spectrometry (GC/MS) Testing Innovation Research Development
21
CURRENT FAEE PROFILE Linoleate (C18:2) Palmitate (C16:0)
Linolenate (C18:3) Arachidonate (C20:4) Palmitate (C16:0) Palmitoleate (C16:1) Stearate (C18:0) Oleate (C18:1) Testing Innovation Research Development
22
FAEE’S IDENTIFY A POTENTIAL HIGH RISK NEWBORN POPULATION
Testing Innovation Research Development
23
USE OF FAEE’s IN MECONIUM
Determination of fetal alcohol exposure in utero Measure FAEE in fetal meconium Window of measure > 20 weeks Indicates alcohol usage during last half of pregnancy Used by neonatologists when fetal alcohol exposure suspected Testing Innovation Research Development
24
FUTURE POTENTIAL APPLICATIONS FOR EtG, FAEE’s, AND PHOSPHATIDYLETHANOL AS DIRECT ALCOHOL BIOMARKERS
Testing Innovation Research Development
25
FAEE IN HAIR Potential biomarker for long-term alcohol abuse (up to 3 months) Control group: <1 drink daily Patient group: drinks daily Hair specimens collected with interview 1.5 inches in length 100 mg in mass Obtained Timeline Followback for 90 days Testing Innovation Research Development
26
FAEE’s MEASURED FAEE’s separated and detected by GC/MS
Ethyl myristate (E14:0) Ethyl palmitate (E16:0) Ethyl palmitoleate (E16:1) Ethyl stearate (E18:0) Ethyl oleate (E18:1) Testing Innovation Research Development
27
FAEE IN HAIR Testing Innovation Research Development
28
FAEE IN HAIR Group N *Alcohol Sensitivity Specificity (drinks/day) (%) (%) Patients 25 11 10 60 100 Female 6 17 19 83 100 Male 19 9 5 53 100 Testing Innovation Research Development
29
CONCLUSIONS OF FAEE IN HAIR STUDY
Hair FAEE’s very specific biomarkers of long term alcohol abuse Sensitivity of hair FAEE’s (60%) is not sufficiently sensitive as an assay to identify individuals with a history of long term alcohol abuse Testing Innovation Research Development
30
EtG IN HAIR Control group: teetotalers
Patient group: individuals in alcohol abuse programs Hair specimens collected with interview 1.5 inches in length 100 mg in mass Obtained Timeline Followback for 90 days Testing Innovation Research Development
31
EtG IN HAIR ANALYSIS Hair specimens washed sequentially with hexane, methylene chloride, and methanol Hair specimens extracted with water EtG partially purified from water extracts by solid phase extraction EtG resolved from water residue and identified using LC/MS/MS Testing Innovation Research Development
32
HAIR EtG IN CONTROLS AND PATIENTS
Testing Innovation Research Development
33
COMPARISON OF FAEE’s AND EtG IN HAIR AS ALCOHOL BIOMARKERS
Testing Innovation Research Development
34
PATIENTS TESTING NEGATIVE FOR HAIR FAEE’s BUT POSITIVE FOR HAIR EtG
Testing Innovation Research Development
35
CONCLUSIONS OF EtG IN HAIR STUDY
Hair EtG very specific biomarker of long term alcohol abuse Sensitivity of hair EtG (80%) is better than any long term marker of alcohol abuse currently available Our Phase I study establishes feasibility of hair EtG as a long term alcohol biomarker paves the way for a Phase II study to expand and diversify the drinking population studied and validate a hair EtG production test Testing Innovation Research Development
36
PHOSPHATIDYLETHANOL Alcohol biomarker in umbilical cord tissue
Alcohol biomarker in newborn blood spots Two research studies sponsored by Phase I SBIR grants from NIH/NIAAA Testing Innovation Research Development
37
PHOSPHATIDYLETHANOL IN UMBILICAL CORD TISSUE
Virtues of umbilical cord tissue as opposed to meconium in drug/alcohol testing of newborns Easier and more dependable collection Greater sensitivity for certain drugs Availability of umbilical cord from all babies while 8- 20% of newborns lack a meconium sample due to fetal stress Testing Innovation Research Development
38
PHOSPHATIDYLETHANOL IN UMBILICAL CORD TISSUE
FAEE’s are the direct alcohol biomarker found in meconium; phosphatidylethanol not detected in meconium Phosphatidylethanol is the direct alcohol biomarker found in umbilical cord tissue; FAEE’s present in umbilical cord tissue, but in very low amounts Testing Innovation Research Development
39
PHOSPHATIDYLETHANOL IN NEWBORN BLOOD SPOTS
Newborns at high risk for fetal alcohol effects (FAE) Approximately 126,000 born in 2006 Costs for medical, surgical, behavioral, custodial, and judicial services for FAE children estimated to range between $75 million and $9.7 billion in 2000 Current “gold standard” alcohol biomarker test to aid in identifying these high risk babies has a sensitivity of 68% Testing Innovation Research Development
40
CRITERIA THAT INITIATES TESTING OF NEWBORNS FOR ALCOHOL OR DRUGS OF ABUSE EXPOSURE
No permanent address Presence of sexually transmitted disease(s) Mother or father appear intoxicated, “high”, abusive, or exhibiting inappropriate behavior Previous maternal history of drug/alcohol abuse Maternal self-report of drug/alcohol usage during current pregnancy No prenatal care Testing Innovation Research Development
41
DO THESE CRITERIA WORK IN IDENTIFYING DRUG/ALCOHOL EXPOSED NEWBORNS?
In the case of drugs of abuse YES Incidence of exposure in sequential births 10% or less Incidence when one or more criteria apply 35% or greater In the case of alcohol exposure NO Incidence of exposure in sequential births % Incidence when one or more criteria apply % Testing Innovation Research Development
42
PHOSPHATIDYLETHANOL IN NEWBORN BLOOD SPOTS
Potential screening test for detecting FAE newborns with high sensitivity and specificity Phase I NIAAA SBIR grant to determine the feasibility of this test was recently awarded Testing Innovation Research Development
43
USDTL RESEARCH FUNDING
NIH SBIR Grants from National Institute of Drug Abuse National Institute on Alcohol Abuse and Alcoholism Testing Innovation Research Development
44
QUESTIONS? Testing Innovation Research Development
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.